Form 10-Q · Quarterly report
Moody's Corporation 10-Q, filed Oct 21, 2026
- Filed
- CIK
- 0001059556
- Accession no.
- 0001628280-26-066731
Summary
Moody's Corporation reported third-quarter 2026 revenue of $2.02 billion, up 1% from a year earlier, and net income attributable to Moody's of $734 million, or $4.24 per diluted share, helped by a $115 million gain on the divestiture of its MA Regulatory Solutions business. Moody's Analytics external revenue rose 3% while Moody's Investors Service revenue fell 1%, and operating margin narrowed to 44.8%.
Key points
- Total revenue was $2.023 billion versus $2.007 billion a year earlier; Moody's Analytics external revenue was $936 million, up 3%, while Moody's Investors Service revenue was $1.087 billion, down 1%.
- Net income attributable to Moody's was $734 million, and diluted EPS rose to $4.24 from $3.60; adjusted diluted EPS rose to $4.14 from $3.92.
- Operating margin was 44.8%, down 90 basis points, and adjusted operating margin was 52.6%, down 30 basis points.
- The company recorded a $115 million gain on business divestitures tied to MA Regulatory Solutions, and total headcount was 15,636, down 2% from a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion RESULTS OF OPERATIONS The following footnotes are applicable throughout the discussion of the Company's results of operations: (1) Refer to the section entitled "Non-GAAP Financial Measures" of this MD&A for the definition and methodology that the Company utilizes to calculate this metric. (2) Refer to the section entitled "Key Performance Metrics" of this MD&A for the definition and methodology that the Company utilizes to calculate this metric. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.